Dr Jeff Davies appointed as non-executive directorMelbourne,...

Dr Jeff Davies appointed as non-executive director
Melbourne, Australia; 1 April 2022: Starpharma today
announced that Dr Jeff Davies has commenced as an independent non-executive director,
effective 1 April 2022.

Dr Davies is a former CSL executive, with over 35 years of biopharmaceutical experience,
holding senior executive roles at CSL, including Executive Vice President & General Manager
at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and
Development at CSL-Behring, Switzerland. Dr Davies’ experience spans R&D, business
operations, drug development and product commercialisation.

Commenting on his appointment, Dr Davies said:

“I am delighted to join Starpharma’s board having been impressed by the company and its
technology for a number of years as a shareholder. Starpharma’s deep portfolio of DEP®
oncology products and partnerships are particularly impressive.

“I also consider VIRALEZE™ to be a really interesting product opportunity and its rapid
development and launch is a testament to Starpharma’s capable team. Having held various
roles at CSL across three decades, I recognise the value of Starpharma’s technology, strategy
and its innovative products, which have the potential to drive significant commercial value. I
look forward to working with the Board and management team at this exciting time for
Starpharma.”